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TANK-binding kinase 1 (TBK1) loss-of-function (LoF) mutations are known to cause frontotemporal
dementia (FTD) and amyotrophic lateral sclerosis (ALS), often combined with memory deﬁcits early in
the disease course. We performed targeted resequencing of TBK1 in 1253 early onset Alzheimer’s disease
(EOAD) patients from 8 European countries to investigate whether pathogenic TBK1 mutations are
enriched among patients with clinical diagnosis of EOAD. Variant frequencies were compared against
2117 origin-matched controls. We identiﬁed only 1 LoF mutation (p.Thr79del) in a patient clinically
diagnosed with Alzheimer’s disease and a positive family history of ALS. We did not observe enrichment
of rare variants in EOAD patients compared to controls, nor of rare variants affecting NFkB induction. Of 3
common coding variants, rs7486100 showed evidence of association (OR 1.46 [95% CI 1.13e1.9]; p-value
0.01). Homozygous carriers of the risk allele showed reduced expression of TBK1 (p-value 0.03). Our
ﬁndings are not indicative of a signiﬁcant role for TBK1 mutations in EOAD. The association between
common variants in TBK1, disease risk and reduced TBK1 expression warrants follow-up in FTD/ALS
cohorts.
 2017 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
TANK-binding kinase 1 (TBK1) is a serine/threonine-protein ki-
nase involved in autophagy and inﬂammatory response (Weidberg
and Elazar, 2011). TBK1 interacts with the optineurin (OPTN) pro-
tein and with multiple interferon regulatory factors, mediating NF-
kappa-B (NFkB) activity (Cirulli et al., 2015; Clement et al., 2008;
Larabi et al., 2013). Recently, TBK1 has been demonstrated to
regulate mitosis and microtubule stability via the TBK1-CEP170
complex (Pillai et al., 2015).
Loss-of-function (LoF) mutations in the TBK1 gene, including
frameshift mutations and inframe amino acid deletions have been
identiﬁed as a cause of disease in the frontotemporal dementia
(FTD)eamyotrophic lateral sclerosis (ALS) spectrum of neuro-
degeneration (Cirulli et al., 2015; Freischmidt et al., 2015; Gijselinck
et al., 2015). In addition, several missense variants have been re-
ported to lead to loss of function, for example, by inhibiting TBK1
interaction with OPTN (Freischmidt et al., 2015; Pottier et al., 2015).
Recently, missense mutations compromising NFkB activation in the
IFN pathway were found to be enriched among FTD patients
compared with neurologically healthy control individuals, sugges-
tive of intermediate penetrant risk variants (van der Zee et al.,
2017). However, given the range of functions and substrates of
TBK1 and the current absence of insight in the pathomechanism
linking TBK1 LoF to FTD/ALS, causal inferences should bemadewith
caution.
Episodic memory loss and disorientation in time and/or space
appear to be frequent early symptoms in carriers of a pathogenic
TBK1 LoFmutation (VanMossevelde et al., 2015), even resulting in a
clinical diagnosis of Alzheimer’s disease (AD) in some carriers
(Pottier et al., 2015; Van Mossevelde et al., 2015). This has led to the
recommendation to consider genetic diagnostic testing for TBK1LoF mutations in case of clinical ambiguity between FTD and AD
(Van Mossevelde et al., 2015).
Here, we report a massive parallel resequencing of TBK1 in a
large European cohort consisting of 1253 early-onset AD (EOAD)
patients, and comparison with 2117 origin-matched unaffected
control individuals, to investigate to what extent genetic variability
in TBK1 contributes to the occurrence of AD.2. Materials and methods
2.1. Study population
The cohort under study consisted of 1253 EOAD patients origi-
nating from Flanders-Belgium (n ¼ 273), Spain (n ¼ 375), Portugal
(n ¼ 104), Italy (n ¼ 182), Sweden (n ¼ 155), Greece (n ¼ 62),
Germany (n ¼ 91), and Czech Republic (n ¼ 11) and 2117 age-
matched European control individuals originating from Flanders-
Belgium (n ¼ 1042), Spain (n ¼ 334), Portugal (n ¼ 124), Italy
(n ¼ 340), and Sweden (n¼ 277) (Table 1). A detailed description of
cohort procedures and characteristics is provided in (Verheijen
et al., 2016). In the patient cohort, average onset age was 58.9 
6.2 years. Information on familial history of ADwas present for 756/
1253 (60%) patients. Of these, 338/756 (45%) individuals had a
positive familial history (deﬁned as presence of at least 1 ﬁrst-
degree relative with AD). Patients with known pathogenic muta-
tions in genes APP, PSEN1, PSEN2, ABCA7, C9orf72, MAPT, PRNP, and
GRN were excluded from the cohort (Cruts et al., 2012; Cuyvers
et al., 2015a) (Cuyvers et al., 2015). Average age at inclusion for
the control cohort was 67.5  10.0 years. The percentage of women
was 59% for both the patient and the control cohort.
Table 1
Cohort characteristics
Country of origin Patients (n ¼ 1253) Controls (n ¼ 2117)
Belgium n ¼ 273 n ¼ 1042
57% female 60% female
AAO ¼ 63.5  6.4 AAI ¼ 71.5  9.8
Spain n ¼ 375 n ¼ 334
58% female 57% female
AAO ¼ 57.8  4.8 AAI ¼ 57.9  4.9
Italy n ¼ 182 n ¼ 340
66% female 61% female
AAO ¼ 56.7  7.1 AAI ¼ 64.6  8.9
Portugal n ¼ 104 n ¼ 124
61% female 69% female
AAO ¼ 56.9  6.3 AAI ¼ 66.3  6.1
Sweden n ¼ 155 n ¼ 277
63% female 59% female
AAO ¼ 57.9  4.6 AAI ¼ 64.2  5.5
Greece n ¼ 62 n ¼ 0
61% female
AAO ¼ 58.1  3.7
Germany n ¼ 91 n ¼ 0
52% female
AAO ¼ 58.6  4.7
Czech republic n ¼ 11 n ¼ 0
45% female
AAO ¼ 59.1  7.7
Key: AAI, age at inclusion (years standard deviation); AAO, age at onset.
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consents
All participants and/or their legal guardian gave written
informed consent for participation in clinical and genetic studies.
Autopsied patients or their legal guardian gave written informed
consent for inclusion in neuropathological studies. Clinical study
protocol and the informed consent forms for patient ascertainment
were approved by the ethic committee of the respective hospitals at
the cohort sampling sites. The genetic study protocols and informed
consent forms were approved by the Ethics Committees of the
University of Antwerp and the University Hospital of Antwerp,
Belgium.
2.3. Genotyping
Sequencing of the TBK1 coding region in EOAD patients was
performed by target enrichment using MASTR technology (Multi-
plicom, Niel, Belgium) followed by Illumina sequencing. Details are
provided in Supplementary Information. Sequence data of TBK1
coding region were already available for 2117 control individuals,
generated using the same procedures and equipment, and reported
in the study by van der Zee et al. (2017). Shared ancestry of muta-
tion carriers was determined using short tandem repeat genotyp-
ing, as described in the Supplementary Information.
2.4. RNA sequencing
RNA sequencing datawere available for 58 AD patients (28 [48%]
women, mean age at blood sampling 72  4.9 years, and 29 [50%]
APOE 34-positive) and age-matched and ethnicity matched control
individuals (8 [50%] women, mean age at blood sampling 75 
6.2 years, and 8 [50%] APOE 34-positive) (Supplementary Table 1).
RNA sequencing was performed on poly-A selected total RNA
derived from lymphoblast cells using an Illumina HiSeq2000
sequencer as previously described (Verheijen et al., 2016). A
detailed description of sequencing procedures can be found in the
Supplementary Information.2.5. Statistical analysis
Low frequency (minor allele frequency [MAF] between 0.01 and
0.05) and common (MAF0.05) variants located in the TBK1 coding
region were tested for deviations from Hardy-Weinberg Equilib-
rium using PLINK (Purcell et al., 2007). Allele frequencies of com-
mon and low frequency variants in patients and controls were
compared by c2 statistics. Odds ratios and 95% conﬁdence intervals
were calculated by logistic regression modeling, corrected for
gender and APOE ε4 allele carrier status for each country of origin
separately using PLINK, including individuals originating from
Spain, Italy, Portugal, Sweden, and Belgium (n ¼ 1015 patients and
n ¼ 1977 controls). Individuals originating from Czech Republic (11
patients, 0 controls), Greece (62 patients, 0 controls), and Germany
(91 patients, 0 controls) were excluded from the analysis based on
cohort size. Fixed-effects meta-analysis was performed using the R
package rmeta. Nominal p-values were corrected for the number of
variants tested using Bonferroni correction.
The effect of rare TBK1 variants (MAF <0.01) on AD risk was
assessed using an aggregation test on the same cohorts. Rare
variant association analysis was performed across the full TBK1
coding sequence and separately for each functional protein domain
using an optimized Sequence Kernel Association Test (SKAT-O test),
adjusted for sample size <2000, using the R package SeqMeta.
SKAT-O meta-analysis was performed using standard beta weights,
and included correction for gender and APOE ε4 carrier status of
included individuals. Correction for multiple testing was performed
using Sidák correction. Functional protein domains were deter-
mined according to the study by Gijselinck et al. (2015) and
correspond to National Center for Biotechnology Information
(NCBI) reference sequence NP_037386.1. Differences in TBK1
expression were calculated using an unpaired nonparametric
(Mann-Whitney) test.2.6. In vitro NFkB activity
The effect of mutant TBK1 on NFkB activity in the IFN pathway
was investigated by in vitro luciferase assay as previously described
(van der Zee et al., 2017). A detailed description is provided in the
Supplementary Information.
3. Results
3.1. TBK1 mutation screening
We analyzed the coding sequence of TBK1 in 1253 European
early onset AD patients and 2117 origin-matched control in-
dividuals and identiﬁed 32 rare variants (MAF<0.01) in a total of 47
individuals, of whom 18 (38%) were patients (Supplementary
Tables 2 and 3). In addition, we identiﬁed 2 low-frequency vari-
ants (MAF 0.01e0.05; 1 missense, 1 synonymous) and 1 synony-
mous common variant (MAF 0.05) (Supplementary Table 4).
The 32 rare variants included 1 LoF mutation (p.Thr79del) and
31 missense variants (Fig. 1). The LoF mutation and 7 of the 31
missense variants were only observed in the patient cohort and
were all singleton variants with the exception of p.Ile397Thr, which
was observed in 2 patients. In addition, 6 rare missense variants
(19%) were present in both patient and controls, and 18 variants
(58%) were exclusive to controls. Of the 7 patient-speciﬁc missense
variants, 4 (57%) attained combined annotation dependent deple-
tion (CADD) Phred score >20, whereas 11 of 17 (65%) control-
speciﬁc variants and 4 of 6 (67%) shared variants attained CADD
Phred score >20 (Supplementary Tables 2 and 3).
Fig. 1. Nonsynonymous rare TBK1 variants identiﬁed in EOAD patients and control individuals. Variants in red denote variants present in patient cohort only. Variants in green
denote variants present in both the patient and control population. Variants in blue denote variants present in the control population only. Functional domains are adapted from
(Gijselinck et al., 2015), and based on uniprot information. Protein-level variant position is based on NP_037386.1. Here, (n ¼) depicts number of carriers in the patient/control
cohort. Abbreviations: CT domain, C-terminal domain; SD domain, scaffold dimerization domain; Ub-like domain, ubiquitin-like domain. (For interpretation of the references to
color in this ﬁgure legend, the reader is referred to the Web version of this article.)
Fig. 2. Impact of mutant TBK1 on NFkB activity in the IFN pathway. NFkB activity is
shown for all patient only, shared patient/control and control only rare variants
identiﬁed. Y-axis represents activity of NFkB relative to the reference wild type TBK1
vector transfection condition. Bars in brown reﬂect variants present in the kinase
domain, bars in yellow reﬂect variants present in the ubiquitin-like domain, bars in
green reﬂect variants present in the scaffold dimerization domain, and bars in blue
represent variants present in the C-terminal domain. Asterisks above the bars indicate
signiﬁcant difference from the wild-type level after Bonferroni correction (p < 0.001).
Mock refers to empty vector containing no TBK1. Error bars depict standard deviation.
Abbreviation: WT, wild-type TBK1 vector. (For interpretation of the references to color
in this ﬁgure legend, the reader is referred to the Web version of this article.)
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carrier
TBK1 p.Thr79del is a previously reported LoF mutation (van
der Zee et al., 2017), which we observed in a patient of Spanish
origin. The patient was clinically diagnosed with sporadic EOAD
at age 62 years, with onset of ﬁrst symptoms at 59 years. His
clinical evaluation was considered consistent with AD-type de-
mentia because of the following symptoms: (1) ﬁrst symptoms
were spatial disorientation and recent memory deﬁcits; (2)
cognitive evaluation (Supplementary Table 5) showed signiﬁcant
memory problems and deﬁcits attributed to posterior cortex
(visuospatial and visuoconstructive deﬁcits); and (3) CT scan
showed mild increase of the temporal horns, which could be an
indirect sign of mesial temporal atrophy. At that time (2005), no
CSF biomarker analysis or magnetic resonance imaging was
performed. Repeated neuropsychological evaluation after 2 years
showed a progressive cognitive decline still consistent with AD.
Five years after onset of ﬁrst symptoms, frontal features (hyper-
phagia, logopenia, and apraxia) became apparent, followed by
bilateral parkinsonism at late stages (8 years after onset). The
patient died at 69 years with no autopsy. Two siblings were later
diagnosed with ALS with predominant bulbar signs. For one of
the siblings diagnosed with ALS after the decease of this patient,
mutation screening has been performed, conﬁrming the presence
of TBK1 p.Thr79del. We previously identiﬁed this mutation in an
unrelated Spanish FTD-ALS patient (van der Zee et al., 2017), who
presented with a behavior disorder and was diagnosed with FTD
fulﬁlling Rascovsky criteria. After 3 years, he developed rapidly
progressive bulbar muscle weakness. Brain autopsy revealed
frontolobar degeneration with TDP-43 positive inclusions and
argyrophilic grain disease (stage III). Allele sharing analysis using
a panel of ﬂanking short tandem repeat markers indicated that
the 2 mutation carriers have a common distant ancestor
(Supplementary Table 6).3.3. Effect of rare TBK1 variants on NFkB activation
The effect of the identiﬁed rare variants on NFkB induction was
assessed in vitro by a luciferase reporter assay (Fig. 2). This included
14 TBK1 variants, that is, the inframe deletion p.Thr79del, all 7 rare
missense variants identiﬁed in the patient population, and all 6
missense variants identiﬁed in the patient/control population. The
effects of the 18 rare missense variants identiﬁed in the control
population only were previously reported, using the same pro-
cedures and equipment (van der Zee et al., 2017).We observed
reduced NFkB induction for 5 variants, which included 2 variants
observed only in the patient cohort, p.Thr79del and p.Ile418Val.
Table 2
Meta-analysis of TBK1 rare variant burden
Country of origin Rare alleles/total
alleles patients
Rare alleles/total
alleles controls
SKAT-O
p-value
Belgium 5/534 (0.9%) 12/2064 (0.6%) 0.4
Spain 4/650 (0.6%) 6/592 (1.0%) 0.5
Italy 2/358 (0.6%) 1/592 (0.2%) 0.6
Portugal 2/196 (1.0%) 1/160 (0.6%) 0.6
Sweden 2/292 (0.7%) 4/546 (0.7%) 0.2
SKAT-O meta-analysis
p-value
15/2030 (0.7%) 24/3954 (0.6%) 0.3
Rare variant burden analysis was performed using SKAT-O meta-analysis corrected
for gender and APOE ε4 status, including individuals originating from Belgium, Spain,
Italy, Portugal, and Sweden with nonmissing information on gender and APOE ε4
status. Individuals originating from Greece, Germany, and Czech Republic were
excluded from analysis due to subthreshold cohort size. Percentages are based on
alleles.
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disruption of NFkB activity to 8.6 1.1% of wild-type control activity
level (p-value < 0.0001) (Fig. 2). Missense variant p.Ile418Val,
located in the scaffold dimerization domain, showed reduced NFkB
induction to 63.4  11.6% of wild type control level (p-value 0.001).
This mutation was detected in a Spanish sporadic patient with very
early disease onset (48 years). A third variant, p.Lys291Glu, located
in the kinase domain and showing reduced NFkB activation to
32.0  4.0% (p-value < 0.0001), was detected in 1 patient (a
Swedish female sporadic patient, onset age 52 years) and in 2 un-
affected Belgian control individuals aged 67 and 70 years at inclu-
sion. In addition, 2 missense variants speciﬁc to the control
population showed reduction of NFkB activation (p.Gly16Asp [near
complete reduction] and p.Arg143His [74.8  3.0%]). Both variants
are located in the kinase domain. Interestingly, 3 control-only
missense variants showed an increase of NFkB activation. Two of
these variants, p.Phe56Ser and p.Ile73Val are located within the
kinase domain, whereas one p.Asn455Ser is located within the
scaffold dimerization domain (Supplementary Table 3).
3.4. Rare variant association analysis
The frequency of rare variants in TBK1was 1.4% (18/1253) in the
patient cohort and 0.6% (8/1253) for patient-only variants. Muta-
tion frequency in the control cohort was 1.4% (29/2117) and 0.9%
(20/2117) for control-only variants. Mutation frequency in patients
with known familial history of AD was 1.5% (5/338) and 0.9%
(3/338) for patient-only variants. SKAT-O meta-analysis performed
across the entire TBK1 coding region and for each of the 4 TBK1
protein domains separately showed no signiﬁcant enrichment of
rare variants in patients (SKAT-O p-value 0.3; Table 2,
Supplementary Table 7). When limiting the analysis to the pre-
dicted most deleterious variants (CADD Phred score >20), we
observed nominal signiﬁcant enrichment of rare mutations in pa-
tients for the TBK1 scaffold dimerization domain (SKAT-O p-value
0.04), although we should note the small number of variant carriers
included in this test (n ¼ 6) (Supplementary Tables 8 and 9).
3.5. Single-variant association analysis of low-frequency and
common variants
Two low-frequency variants were located in the TBK1 coding
region, rs35635889 (p.Val464Ala) and rs41292019 (p.Asn22Asn)
(Hardy-Weinberg p-value 0.55 and 0.19, respectively), and 1
common synonymous variant rs7486100 (p.Ile326Ile) (MAF
patients ¼ 0.47; MAF controls ¼ 0.42; Hardy-Weinberg p-value
0.49). Single-variant logistic regression analysis showed signiﬁcant
association between the rs7486100-T allele and EOAD in a recessivemodel (OR 1.46 95% CI [1.13e1.9], Bonferroni-corrected p value
0.012) (Supplementary Table 4A). All 3 variants were subsequently
tested for disease association in a European FTD/FTD-ALS/ALS
cohort previously described in (van der Zee et al., 2017). However,
none of the variants showed association after correction for mul-
tiple testing in this cohort (Supplementary Table 4B). Homozygous
rs7486100-TT carriers demonstrated decreased TBK1 expression
levels in lymphoblast cell lines (2575 normalized read counts
[standard error 188.9], n ¼ 11) compared to AA and AT carriers
(2932 [standard error 66.5], n ¼ 66, Mann-Whitney p-value 0.028)
(Supplementary Fig. 1).
4. Discussion
TBK1 LoF mutations have recently been identiﬁed as an impor-
tant cause of FTD and ALS, with a notable tendency of carriers to
display memory deﬁcits early in the disease course. In addition,
TBK1 is regarded extremely intolerant of LoFmutations according to
the Exac database (pLI ¼ 1) (Lek et al., 2016). We performed a
systematic screening of the coding sequence of TBK1 in a large
European cohort of 1253 EOAD patients to investigate the fre-
quency of TBK1 LoF mutations in AD patients, whether due to
confounding of clinical presentation or due to a direct effect on AD
risk. In contrast to studies on FTD and ALS reporting mutation
frequencies from 1% to 4% (Cirulli et al., 2015; Freischmidt et al.,
2015; Gijselinck et al., 2015; Pottier et al., 2015), we detected only
1 TBK1 LoF mutation among EOAD patients, in a Spanish patient
clinically diagnosed with EOAD (p.Thr79del; overall LoF carrier
frequency 0.08%). TBK1 p.Thr79del is an inframe deletion located in
the kinase domain of TBK1, which was demonstrated to result in
LoF due to a 50% reduction of TBK1 protein in postmortem human
brain, reduction of TBK1 protein expression and absence of
phospho-TBK1 in HEK293T cells overexpressing this mutation, and
loss of NFkB activation (van der Zee et al., 2017). The samemutation
was previously identiﬁed in an apparently unrelated FTD/ALS pa-
tient of the same nationality ascertained at a different research
center (van der Zee et al., 2017). Of note, clinical follow-up of the AD
patient carrying this mutation revealed symptoms compatible with
FTD later in the course of the disease. Two siblings developed ALS,
of which one could be tested genetically andwas conﬁrmed to carry
the TBK1 p.Thr79del mutation. Unfortunately, the diagnostic pro-
cedure of the index patient did not include biomarker analyses that
could support either AD or FTLD diagnosis, and no autopsy was
performed. The presence of the pathogenic TBK1 mutation, how-
ever, suggests that this patient may represent an example of the
atypical clinical presentation previously reported among FTD pa-
tients carrying a pathogenic TBK1 LoF mutation (Pottier et al., 2015;
Van Mossevelde et al., 2015). Although carriers of mutations in APP,
PSEN1, PSEN2, ABCA7, C9orf72, MAPT, PRNP, and GRN were excluded
from the study, we cannot exclude the possibility that the clinical
phenotype of neurodegeneration in this patient was caused or
modiﬁed by an as yet unknown mutation.
We did not observe an enrichment of rare variants in EOAD
patients compared to controls (carrier frequency of 1.4% in both), in
line with previous association studies performed on FTD and ALS
patients (Freischmidt et al., 2015). Rare variants exclusively
observed in patients were not more often novel and/or predicted to
be pathogenic (based on CADD score) than rare variants only
observed in controls. In addition, missense mutations with
compromised NFkB activation capacity that have recently been
proposed as rare risk variants for FTD (van der Zee et al., 2017) were
not enriched among EOAD patients. Only 2 missense variants
identiﬁed in patients resulted in reduced NFkB induction. One of
those (p.Ile418Val) was observed in a patient with a clinical diag-
nosis of AD with very early onset age. The mutation affects the
J. Verheijen et al. / Neurobiology of Aging 62 (2018) 245.e1e245.e7245.e6scaffold dimerization domain and showed a modest effect on NFkB
activation. Interaction between the scaffold dimerization domain
and the kinase domain is required for TBK1 kinase activity and
transphosphorylation activity in vitro (Shu et al., 2013). In absence
of a positive family history, we were unable to further investigate
the genetic evidence of pathogenicity of this mutation. The other
mutation (p.Lys291Glu) showing decreased NFkB induction is
located within the kinase domain. This mutation was detected in 1
patient and 2 control individuals. Both control-only missense var-
iants disrupting NFkB activation, p.Gly16Asp, and p.Arg143His are
also located within the kinase domain. Of note, it is presently un-
knownwhether loss of NFkB activation is the molecular mechanism
linking TBK1 LoF mutations to neurodegeneration. Therefore, these
results should be interpreted with caution. Nonetheless, lack of
association between EOAD and rare TBK1 missense variants,
whether or not predicted or demonstrated to affect TBK1 func-
tionality, argues against a signiﬁcant role of rare TBK1 variants in
EOAD.
No associations of TBK1 common and low frequency variants
with dementia spectrum disorder diagnoses have yet been re-
ported. In our meta-analysis covering EOAD cohorts originating
from 5 European countries, a common synonymous variant
(rs7486100) showed association in a recessive model. In light of the
hypothesis that loss of TBK1 can contribute to neurodegeneration,
we tested the effect of the risk allele on TBK1 expression. Inter-
estingly, RNA sequence analysis on lymphoblast cell lines of ho-
mozygous carriers of the risk-increasing allele rs7486100-T showed
decreased TBK1 expression. In line with this, carriers of the
rs7486100-T allele showed decreased expression of TBK1 in mul-
tiple tissues according to the Gtex database, with lowest expression
levels in homozygous rs7486100-T carriers. This variant tags a
w150 kb region of strong linkage disequilibrium extending to the
ﬂanking genes, and there is no evidence supporting a direct
regulatory effect of rs7486100 (RegulomeDB score 6), warranting
further investigation of common eQTLs in the region and their
association with neurodegeneration spectrum disorders. Of
note, however, rs7486100 did not show association with late-onset
AD in a meta-analysis of genome-wide association studies
(Lambert et al., 2013).
In conclusion, this investigation of common and rare variants in
TBK1 in a large European cohort of EOAD indicates that genetic
variability in TBK1 does not contribute signiﬁcantly to the risk of
EOAD. A common variant associated with decreased TBK1 expres-
sion may be enriched in EOAD patients compared to controls, but
this requires further conﬁrmation given the lack of association in
late-onset AD. In diseases with stronger evidence of a genetic link
between TBK1 LoF and neurodegeneration, such as FTD and ALS,
further investigation of common variants affecting TBK1 expression
is warranted. Our data revealed only 1 TBK1 LoF variant among
1253 EOAD patients (LoF carrier frequency 0.08%), in a patient
without a biomarker-supported or autopsy-conﬁrmed diagnosis of
AD. In light of the development of frontal features later in the
course of the disease, this leaves open the possibility that this pa-
tient had FTLD with atypical clinical presentation due to early
symptoms compatible with AD, in line with previous identiﬁcation
of TBK1 LoF variants in FTD/ALS patients with initial clinical diag-
nosis of AD (Pottier et al., 2015; Van Mossevelde et al., 2015).
Missense mutations leading to signiﬁcant reduction of NFkB
activation were detected in AD patients, but despite the fact that
these mutations may act as risk alleles in FTD (van der Zee et al.,
2017), they were not signiﬁcantly enriched in EOAD patients
compared to controls. Although our ﬁndings do not support a role
for TBK1 in the pathogenesis of EOAD, the recurring ambiguity of
clinical diagnosis in carriers of pathogenic TBK1 mutationsnecessitates further research on the clinical presentation of TBK1
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